TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Details
01. General Information
Name SMC3
Drug Type Not Available
Toxicity Organism Test Type Route(Dose)
Structure 2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 842
Ref_1
Pair Name Luteolin, SMC3
Partner Name Luteolin
Disease Info [ICD-11: 2C25.Z] Lung cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Expression BCL-xL hsa598
Up-regulation Cleavage CASP3 hsa836
Up-regulation Cleavage CASP8 hsa841
Up-regulation Cleavage PARP1 hsa142
Down-regulation Expression SOD2 hsa6648
Down-regulation Activity NFKB1 hsa4790
In Vitro Model NCI-H23 Lung adenocarcinoma Homo sapiens (Human) CVCL_1547
Result The results suggest that combination of SMC3 and luteolin is an effective approach for improving the anticancer value of SMC3, which has implications in cancer prevention and therapy.
03. Reference
No. Title Href
1 Attenuating Smac mimetic compound 3-induced NF-kappaB activation by luteolin leads to synergistic cytotoxicity in cancer cells. J Cell Biochem. 2009 Dec 1;108(5):1125-31. doi: 10.1002/jcb.22346. Click
It has been 197052 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP